Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy-Refractory, Advanced Colorectal Cancer

Andrew Weickhardt(Peter MacCallum Cancer Centre), Niall C. Tebbutt(Peter MacCallum Cancer Centre)

Journal of Clinical Oncology

March 13, 2012

10.1200/jco.2011.38.6599

Cited by 109

Related Papers

<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

|New England Journal of Medicine|2008|3.6k

Cetuximab for the Treatment of Colorectal Cancer

|New England Journal of Medicine|2007|1.8k

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2018|1.3k

Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma

|JAMA|2012|590

Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

|Journal of Clinical Oncology|2010|417